Cell Therapeutics’ US subsidiary Aequus BioPharma has appointed Ronald Berenson as president and CEO.
In his new role he will be tasked with expanding Washington State-based Aequus’ GlycoPolymer technology, which aims to create novel biopharmaceuticals with improved pharmacokinetic properties that require less frequent injections than current treatments.
Berenson said: “There are more than 100 therapeutic proteins on the market, and they represent one of the fastest growing classes of drugs today. Patient convenience and compliance continue to be issues with therapeutic proteins due to the need for frequent injections.
“I believe that Aequus’s novel approach could address these challenges with the potential to be applied to a wide spectrum of therapeutics.”
Berenson, who was most recently an Entrepreneur in Residence at the University of Washington, has spent more than 20 years in senior biotech management roles.
During this time he co-founded HemaQuest Pharmaceuticals, serving as president and CEO for its first three years, and founded the oncology-focused biotech companies Xcyte Therapies and CellPro.